1. Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer

   • Shun-Lai Li
   • Chia-Hsin Huang
   • Jiunn-Jye Chuu

   PRECLINICAL STUDIES 05 December 2009 Pages: 195 - 206

   

2. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2

   • Ponnuraj Nagendraprabhu
   • Ganapasam Sudhandiran

   PRECLINICAL STUDIES 30 October 2009 Pages: 207 - 224

   

3. Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors

   • Preeti Roy
   • Jasmine George
   • Yogeshwer Shukla

   PRECLINICAL STUDIES 20 November 2009 Pages: 225 - 231

   

4. CYT997 Causes apoptosis in human multiple myeloma

   • Katherine Monaghan
   • Tiffany Khong
   • Andrew Spencer

   PRECLINICAL STUDIES 12 November 2009 Pages: 232 - 238

   

5. Selective proapoptotic activity of polyphenols from red wine on teratocarcinoma cell, a model of cancer stem-like cell

   • Tanveer Sharif
   • Cyril Auger
   • Guy Fuhrmann

   PRECLINICAL STUDIES 27 November 2009 Pages: 239 - 247

   

6. Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

   • Irene V. Bijnsdorp
   • Reto A. Schwendener
   • Godefridus J. Peters

   PRECLINICAL STUDIES Open access 03 December 2009 Pages: 248 - 257

   

7. Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo

   • Yingqi Hua
   • Zhiyu Zhang
   • Zhengdong Cai

   PRECLINICAL STUDIES 27 November 2009 Pages: 258 - 265

   

8. Lupane Triterpenoids—Betulin and Betulinic acid derivatives induce apoptosis in tumor cells

   • Harish Kommera
   • Goran N. Kaluđerović
   • Reinhard Paschke

   PRECLINICAL STUDIES 04 December 2009 Pages: 266 - 272

   

9. Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ β-catenin pathway

   • Pandurangan Ashokkumar
   • Ganapasam Sudhandiran

   PRECLINICAL STUDIES 15 December 2009 Pages: 273 - 284

   

10. Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes

    • Tushar S. Basu Baul
    • Anup Paul
    • Edward R. T. Tiekink

    PRECLINICAL STUDIES 11 December 2009 Pages: 285 - 299

    

11. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4′,5-trimethoxylstilbene-3′-O-phosphate disodium (M410)

    • Yu-Chen Cai
    • Yong Zou
    • Li-Jian Xian

    PRECLINICAL STUDIES 11 December 2009 Pages: 300 - 311

    

12. Temporal evolution of patient characteristics enrolled on phase I trials

    • Afshin Dowlati
    • Madappa Kundranda
    • Pingfu Fu

    PHASE I STUDIES 09 December 2009 Pages: 312 - 315

    

13. Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

    • Anne M. Traynor
    • James P. Thomas
    • Howard H. Bailey

    PHASE I STUDIES 09 December 2009 Pages: 316 - 322

    

14. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

    • Isam Abdel-Karim
    • William K. Plunkett Jr
    • Hagop M. Kantarjian

    PHASE I STUDIES 21 January 2010 Pages: 323 - 331

    

15. A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction

    • Dok Hyun Yoon
    • Hyo Jung Lee
    • Tae Won Kim

    PHASE I STUDIES 30 December 2009 Pages: 332 - 339

    

16. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

    • Qing Zhou
    • Daniel Gustafson
    • D. Ross Camidge

    PHASE I STUDIES 19 January 2010 Pages: 340 - 346

    

17. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer

    • Bhuvaneswari Ramaswamy
    • Ewa Mrozek
    • Eric H. Kraut

    PHASE II STUDIES 21 October 2009 Pages: 347 - 351

18. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618

    • Susanne M. Arnold
    • James Moon
    • Susan G. Urba

    PHASE II STUDIES 25 November 2009 Pages: 352 - 359

    

19. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer

    • Hee Yeon Seo
    • Hyun Joo Lee
    • Jae Hong Seo

    PHASE II STUDIES 27 November 2009 Pages: 360 - 365

    

20. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

    • Chul Kim
    • Jae-Lyun Lee
    • Yoon-Koo Kang

    PHASE II STUDIES 09 December 2009 Pages: 366 - 373

    

21. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma

    • Christopher W. Ryan
    • Jacqueline Vuky
    • Deirdre Nauman

    PHASE II STUDIES 10 December 2009 Pages: 374 - 379

22. Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma

    • Daniel J. Luther
    • Vahagn Ohanyan
    • Anupam Bishayee

    SHORT REPORT 08 October 2009 Pages: 380 - 391

    

23. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines

    • Claudio Celeghini
    • Rebecca Voltan
    • Giorgio Zauli

    SHORT REPORT 04 February 2010 Pages: 392 - 395

    

24. Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer

    • Binbing Ling
    • Lifeng Chen
    • Jian Yang

    SHORT REPORT 30 December 2009 Pages: 396 - 399